DK1123094T3 - Terapeutiske præparater (II) - Google Patents
Terapeutiske præparater (II)Info
- Publication number
- DK1123094T3 DK1123094T3 DK99946906T DK99946906T DK1123094T3 DK 1123094 T3 DK1123094 T3 DK 1123094T3 DK 99946906 T DK99946906 T DK 99946906T DK 99946906 T DK99946906 T DK 99946906T DK 1123094 T3 DK1123094 T3 DK 1123094T3
- Authority
- DK
- Denmark
- Prior art keywords
- patient
- physiologically acceptable
- therapeutic preparations
- acceptable ketosis
- ketosis
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000007976 Ketosis Diseases 0.000 abstract 2
- 230000004140 ketosis Effects 0.000 abstract 2
- WHBMMWSBFZVSSR-GSVOUGTGSA-M (R)-3-hydroxybutyrate Chemical compound C[C@@H](O)CC([O-])=O WHBMMWSBFZVSSR-GSVOUGTGSA-M 0.000 abstract 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000010901 lateral sclerosis Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000005264 motor neuron disease Diseases 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Polyesters Or Polycarbonates (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10037198P | 1998-09-15 | 1998-09-15 | |
| PCT/US1999/021015 WO2000015216A1 (en) | 1998-09-15 | 1999-09-15 | Therapeutic compositions (ii) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1123094T3 true DK1123094T3 (da) | 2007-08-20 |
Family
ID=22279402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK99946906T DK1123094T3 (da) | 1998-09-15 | 1999-09-15 | Terapeutiske præparater (II) |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20010014696A1 (da) |
| EP (1) | EP1123094B1 (da) |
| JP (1) | JP2002524506A (da) |
| KR (1) | KR100805490B1 (da) |
| CN (1) | CN1273129C (da) |
| AT (1) | ATE359069T1 (da) |
| AU (1) | AU767238B2 (da) |
| BR (1) | BR9913680A (da) |
| CA (1) | CA2339941A1 (da) |
| DE (1) | DE69935799T2 (da) |
| DK (1) | DK1123094T3 (da) |
| ES (1) | ES2283133T3 (da) |
| NZ (1) | NZ509739A (da) |
| PT (1) | PT1123094E (da) |
| RU (1) | RU2242227C2 (da) |
| WO (1) | WO2000015216A1 (da) |
| ZA (1) | ZA200101260B (da) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1292294E (pt) * | 2000-05-01 | 2009-06-01 | Accera Inc | Utilização de triglicéridos de cadeia média para tratamento e prevenção da doença de alzheimer |
| US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| AU2004245567B2 (en) | 2003-06-03 | 2011-06-23 | Oxford University Innovation Limited | Nutritional supplements and therapeutic compositions comprising (R)-3-hydroxybutyrate derivatives |
| WO2005021013A1 (ja) * | 2003-09-01 | 2005-03-10 | Earthus, Inc. | β−ヒドロキシ短〜中鎖脂肪酸重合体 |
| US7132221B2 (en) * | 2003-09-12 | 2006-11-07 | Headway Technologies, Inc. | Method to print photoresist lines with negative sidewalls |
| GB0410266D0 (en) * | 2004-05-07 | 2004-06-09 | Ketocytonyx Inc | Treatment of apoptosis |
| GB0420856D0 (en) * | 2004-09-20 | 2004-10-20 | Ketocytonyx Inc | Cns modulators |
| WO2006020179A2 (en) | 2004-07-20 | 2006-02-23 | Ketocytonyx Inc. | Oligomeric ketone compounds |
| DK1796658T3 (da) * | 2004-09-21 | 2016-06-27 | Btg Int Ltd | Dopaminerge mimetika |
| GB0427145D0 (en) * | 2004-12-10 | 2005-01-12 | Ketocytonyx Inc | Compositions for use in surgery |
| WO2007001883A2 (en) | 2005-06-20 | 2007-01-04 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
| PT2500017T (pt) | 2006-04-03 | 2017-11-14 | Accera Inc | Utilização de compostos cetogénicos para tratamento de comprometimento da memória associado à idade |
| RU2317304C1 (ru) * | 2006-04-17 | 2008-02-20 | Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (СО РАН) | Пептид, обладающий апоптотической активностью по отношению к раковым клеткам человека |
| US7807718B2 (en) * | 2006-06-30 | 2010-10-05 | Sami A. Hashim | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
| US20080089981A1 (en) * | 2006-10-17 | 2008-04-17 | N.V. Nutricia | Ketogenic diet |
| JP5504534B2 (ja) * | 2007-03-30 | 2014-05-28 | 有限会社アーザス | ケトン体生成促進剤組成物 |
| RU2459624C2 (ru) * | 2007-04-12 | 2012-08-27 | Риджентс Оф Дзе Юниверсити Оф Миннесота | Защитные композиции от ишемии/реперфузии и способы применения |
| CN101293831B (zh) * | 2007-04-27 | 2013-09-18 | 汕头大学 | 3-羟基脂肪酸及其衍生物在制备钙离子通道调节剂中的用途 |
| CA3078084C (en) | 2007-07-31 | 2023-08-15 | Cerecin Inc. | Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function |
| CA2702577A1 (en) | 2007-10-15 | 2009-04-23 | Jbs United, Inc. | Method for increasing performance of offspring |
| EP2240017B1 (en) * | 2008-01-04 | 2019-03-13 | Oxford University Innovation Limited | Ketone bodies and ketone body esters as blood lipid lowering agents |
| US8105809B2 (en) | 2008-07-03 | 2012-01-31 | Accera, Inc. | Enzymatic synthesis of acetoacetate esters and derivatives |
| WO2010003114A1 (en) | 2008-07-03 | 2010-01-07 | Neuera Pharmaceuticals, Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
| US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
| CA2750510A1 (en) | 2009-01-24 | 2010-07-29 | Phytopharm Plc | Treatment of neurotrophic factor mediated disorders |
| CN111700901A (zh) * | 2010-01-08 | 2020-09-25 | Ionis制药公司 | 血管生成素样3表达的调节 |
| GB201002983D0 (en) | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
| JP2013543482A (ja) | 2010-07-20 | 2013-12-05 | ファイトファーム ピーエルシー | Ｌ−ドーパ、ドーパミン作動薬及び／又はドーパミン賦活剤により誘発される疾患の処置 |
| JP6883384B2 (ja) | 2012-11-05 | 2021-06-09 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 電離放射線による傷害から組織を防護するためのケトン体 |
| GB201304467D0 (en) | 2013-03-12 | 2013-04-24 | Tdeltas Ltd | Compound for use in protecting skin |
| SG11201507685UA (en) | 2013-03-14 | 2015-10-29 | Isis Innovation | Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate |
| MY180761A (en) | 2013-03-19 | 2020-12-08 | Univ South Florida | Compositions and methods for producing elevated and sustained ketosis |
| US10245243B1 (en) | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
| US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
| US10596131B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
| US10596130B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US10245242B1 (en) | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
| US10596129B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
| US10292952B2 (en) | 2016-03-11 | 2019-05-21 | Axcess Global Sciences, Llc | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis |
| US12496283B2 (en) | 2016-04-19 | 2025-12-16 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US12533346B2 (en) | 2016-04-19 | 2026-01-27 | Axcess Global Sciences, Llc | Administration of berberine metabolites |
| US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
| US12599579B2 (en) | 2016-04-19 | 2026-04-14 | Axcess Global Sciences, Llc | Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids |
| US11026929B2 (en) | 2016-04-19 | 2021-06-08 | Keto Patent Group, Inc. | Administration of berberine metabolites |
| US20230346721A1 (en) | 2018-04-18 | 2023-11-02 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies |
| US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
| US12329734B2 (en) | 2017-12-19 | 2025-06-17 | Axcess Global Sciences, Llc | Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow |
| US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
| US12109182B2 (en) | 2016-04-19 | 2024-10-08 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US12622889B2 (en) | 2016-04-19 | 2026-05-12 | Axcess Global Sciences, Llc | S-β-hydroxybutyrate esters for improving metabolic function |
| US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
| US12521378B2 (en) | 2016-04-19 | 2026-01-13 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans |
| US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
| US10307398B2 (en) | 2016-09-20 | 2019-06-04 | Regents Of The University Of Minnesota | Resuscitation composition and methods of making and using |
| CA3046415A1 (en) | 2016-12-21 | 2018-06-28 | Universitats-Kinderspital Beider Basel | Migraine prevention and treatment |
| CN110248652B (zh) * | 2016-12-23 | 2023-05-26 | 鲁汶大学 | 3-羟基丁酸单独或组合用于治疗重症监护治疗 |
| US10376528B2 (en) | 2017-03-10 | 2019-08-13 | Tecton Group, Llc | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor |
| US12171735B2 (en) | 2017-04-19 | 2024-12-24 | Axcess Global Sciences, Llc | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans |
| US11760963B2 (en) | 2017-08-23 | 2023-09-19 | KetoneAid Inc. | Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol |
| US12090129B2 (en) | 2017-11-22 | 2024-09-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| GB2572185A (en) * | 2018-03-21 | 2019-09-25 | Chain Biotechnology Ltd | Pharmaceutical compositions |
| US10512615B1 (en) | 2018-08-27 | 2019-12-24 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
| US10980772B2 (en) | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
| US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
| US12472200B2 (en) | 2019-05-15 | 2025-11-18 | Axcess Global Sciences, Llc | Autobiotic compositions and method for promoting healthy gut microbiome |
| US12167993B2 (en) | 2019-06-21 | 2024-12-17 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
| US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| IT201900022854A1 (it) * | 2019-12-03 | 2021-06-03 | Dr Schaer S P A | Formulazione alimentare e prodotto alimentare da forno per la gestione della dieta chetogenica |
| WO2021195477A1 (en) | 2020-03-27 | 2021-09-30 | Ketoneaid, Inc. | Ketone ester as a therapeutic treatment of covid-19, long covid, and related viral infections |
| US12186297B2 (en) | 2020-08-26 | 2025-01-07 | Axcess Global Sciences, Llc | Compositions and methods for increasing lean-to-fat mass ratio |
| AU2022315496A1 (en) | 2021-07-17 | 2023-12-07 | Ketoswiss Ag | Combination of a ketone body or ketogenic compound with an analgesic or antioxidant |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5286842A (en) * | 1991-07-01 | 1994-02-15 | Mitsubishi Kasei Corporation | Process for producing a biodegradable polymer |
| RU2064793C1 (ru) * | 1992-03-31 | 1996-08-10 | Игорь Васильевич Комиссаров | Стресспротективное средство, обладающее антиамнестическим, антигипоксическим, противотревожным и противошоковым действием |
| JP2885261B2 (ja) * | 1993-05-17 | 1999-04-19 | 三菱瓦斯化学株式会社 | ３−ヒドロキシ酪酸のオリゴマー及びその塩からなる輸液製剤 |
| JP4598203B2 (ja) | 1995-12-01 | 2010-12-15 | ビーティージー・インターナショナル・リミテッド | 脳機能改善剤 |
| DK1017379T3 (da) * | 1997-03-17 | 2015-02-16 | Btg Int Ltd | Terapeutiske sammensætninger omfattende ketonforbindelser og forstadier deraf |
| US6323237B1 (en) * | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
| WO1999034687A1 (en) * | 1998-01-07 | 1999-07-15 | Metabolix, Inc. | Animal nutrition compositions |
| US6380244B2 (en) * | 1998-07-22 | 2002-04-30 | Metabolix, Inc. | Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
-
1999
- 1999-09-15 DK DK99946906T patent/DK1123094T3/da active
- 1999-09-15 EP EP99946906A patent/EP1123094B1/en not_active Expired - Lifetime
- 1999-09-15 NZ NZ509739A patent/NZ509739A/en not_active IP Right Cessation
- 1999-09-15 AT AT99946906T patent/ATE359069T1/de active
- 1999-09-15 DE DE69935799T patent/DE69935799T2/de not_active Expired - Lifetime
- 1999-09-15 CN CNB998108375A patent/CN1273129C/zh not_active Expired - Fee Related
- 1999-09-15 BR BR9913680-5A patent/BR9913680A/pt not_active Application Discontinuation
- 1999-09-15 RU RU2001110097/15A patent/RU2242227C2/ru not_active IP Right Cessation
- 1999-09-15 CA CA002339941A patent/CA2339941A1/en not_active Abandoned
- 1999-09-15 AU AU59212/99A patent/AU767238B2/en not_active Ceased
- 1999-09-15 JP JP2000569800A patent/JP2002524506A/ja active Pending
- 1999-09-15 KR KR1020017003343A patent/KR100805490B1/ko not_active Expired - Fee Related
- 1999-09-15 PT PT99946906T patent/PT1123094E/pt unknown
- 1999-09-15 WO PCT/US1999/021015 patent/WO2000015216A1/en not_active Ceased
- 1999-09-15 ES ES99946906T patent/ES2283133T3/es not_active Expired - Lifetime
-
2001
- 2001-02-14 ZA ZA200101260A patent/ZA200101260B/en unknown
- 2001-03-06 US US09/799,124 patent/US20010014696A1/en not_active Abandoned
-
2003
- 2003-12-15 US US10/734,586 patent/US7351736B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1273129C (zh) | 2006-09-06 |
| AU5921299A (en) | 2000-04-03 |
| ATE359069T1 (de) | 2007-05-15 |
| US20040171671A1 (en) | 2004-09-02 |
| DE69935799D1 (de) | 2007-05-24 |
| HK1035665A1 (en) | 2001-12-07 |
| BR9913680A (pt) | 2001-06-05 |
| EP1123094B1 (en) | 2007-04-11 |
| ZA200101260B (en) | 2001-08-16 |
| WO2000015216A1 (en) | 2000-03-23 |
| DE69935799T2 (de) | 2007-12-27 |
| CN1316902A (zh) | 2001-10-10 |
| NZ509739A (en) | 2003-10-31 |
| PT1123094E (pt) | 2007-06-28 |
| ES2283133T3 (es) | 2007-10-16 |
| US20010014696A1 (en) | 2001-08-16 |
| EP1123094A1 (en) | 2001-08-16 |
| AU767238B2 (en) | 2003-11-06 |
| KR100805490B1 (ko) | 2008-02-20 |
| US7351736B2 (en) | 2008-04-01 |
| RU2242227C2 (ru) | 2004-12-20 |
| EP1123094A4 (en) | 2001-10-04 |
| KR20010079830A (ko) | 2001-08-22 |
| CA2339941A1 (en) | 2000-03-23 |
| JP2002524506A (ja) | 2002-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9913680A (pt) | Composições terapêuticas (ii) | |
| MX9203543A (es) | Medicamento. | |
| DE69713526D1 (de) | Lösliche prodrugs von paclitaxel | |
| KR930702022A (ko) | 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법 | |
| NL300382I1 (nl) | Treatment of pompe's disease | |
| RU94045155A (ru) | Способы ингибирования болезни альцгеймера | |
| EP1019072A4 (en) | ASSISTANCE PROCESS FOR DIFFERENTIAL DIAGNOSIS AND TREATMENT OF AUTISM SYNDROME | |
| DE69532810D1 (de) | Intravenöse alendronatformulierungen | |
| HUP9800467A2 (hu) | Hialuronsav alkalmazása szövetközi cisztitisz kezelésére alkalmas gyógyászati készítmények előállítására | |
| SE8500996D0 (sv) | Method of treatment | |
| EE9700231A (et) | Aminotetraliini derivaat kardiovaskulaarsete haiguste raviks | |
| DE3687742D1 (de) | Verwendung von acetyl-l-carnitin zur herstellung eines arzneimittels zur therapeutischen behandlung von schockzustaenden. | |
| ATE91890T1 (de) | Herstellung eines arzneimittels gegen arthritis und rheumatismus. | |
| ATE207353T1 (de) | Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden | |
| SU1475668A1 (ru) | Способ лечени функциональных поражений лицевого нерва | |
| GR3001565T3 (en) | Medical preparation comprising aspoxicillin, a method for its preparation, and the use of such a preparation for the manufacture of a medicament | |
| RU95103961A (ru) | Способ лечения хронической ишемической болезни сердца | |
| UA10301A (uk) | Спосіб лікуваhhя раку шлуhку | |
| SU1487907A1 (ru) | Способ лечения овуляторных болей | |
| UA30251A (uk) | Спосіб лікування гіпертонії сфінктера одді у хворих на хронічний безкам'яний холецистит при поєднанні з підвищенням тонусу симпатичної нервової системи | |
| UA15281A (uk) | Спосіб лікуваhhя хроhічhої ішемічhої хвороби серця | |
| DK601788A (da) | Anvendelse af antibiotikaene ll-e19020alfa og ll-e19020beta til behandling af visse fjerkraesygdomme | |
| RU2000106699A (ru) | Способ лечения заболеваний методом настройки биоритмов организма | |
| RU2195299C2 (ru) | Способ лечения больных псориазом | |
| Brown | Respiratory arrest after peak expiratory flow measurement |